Notice NOT-DA-21-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-22-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.

Funding Opportunity PA-21-201 from the NIH Guide for Grants and Contracts. Reissue of the PA-18-401. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

Funding Opportunity PA-21-200 from the NIH Guide for Grants and Contracts. Reissue of the PA-18-400. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

Funding Opportunity PA-21-199 from the NIH Guide for Grants and Contracts. Reissue of the PA-18-399. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. An R03 grant application may not contain extensive detail or discussion. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.

Funding Opportunity RFA-AI-21-025 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support projects to improve use of evidence-based HIV prevention interventions among populations in jurisdictions identified as highly impacted by HIV. Research funded under this initiative will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities.

Funding Opportunity RFA-AI-21-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this initiative will support the goals of the DIAGNOSE and TREAT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people living with HIV (PLWH) through better healthcare engagement.

Funding Opportunity RFA-AI-21-023 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

Funding Opportunity RFA-AI-21-009 from the NIH Guide for Grants and Contracts. To encourage multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.

Notice NOT-AI-21-044 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-036 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-21-008 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R43/R44 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.

Those who have been through it share their recommendations—and note pitfalls to avoid

Funding Opportunity RFA-HG-21-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals

Funding Opportunity RFA-HG-21-006 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R01 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.

Competitive Salary: EMBL: About this position ELIXIR is seeking a Technical Coordinator to join the dynamic and international Human Genomics and Translational team at the EL Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: About this position We are seeking a Bioinformatician to join the Data Coordination and Archiving Team at the EMBL-European Bioinformatics Institut Hinxton, Cambridgeshire, England

Notice NOT-OD-21-090 from the NIH Guide for Grants and Contracts

Notice NOT-MD-21-017 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-009 from the NIH Guide for Grants and Contracts